ROUNDUP: Daimler rudert wegen Zollstreit und Dieselaffäre beim Ausblick zurück

SHIRE PLC - Directorate Change

Mittwoch, 15.02.2017 13:30 von PR Newswire

PR Newswire

Directorate change

February 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following changes to Board committee membership, effective immediately:

Director Appointment Resignation
Dominic Blakemore Remuneration Committee N/A
Olivier Bohuon Nomination & Governance Committee Science & Technology Committee
Ian Clark Remuneration Committee;
Science & Technology Committee
Sara Mathew Nomination & Governance Committee Remuneration Committee

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations
Ian Karp +1 781 482 9018
Robert Coates +44 1256 894874
Lisa Adler +1 617 588 8607
Debbi Ford  +1 617 949 9083


About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.